It is no secret that there is a digital transformation happening across life sciences and healthcare. This seismic shift is being facilitated by cutting-edge technology that is enabling the interrogation and aggregation of the vast quantities of data that we now have at our fingertips. The adoption of automated processes using technologies like artificial intelligence (AI), which incorporates human intelligence into machines through a set of rules, and machine learning (ML), an application of AI whereby the computer learns automatically through its experiences, is key to collecting and analyzing the vast and varied data that is now available and facilitating a move to a personalized approach to medicine.
As the ways in which clinical trials are conducted and monitored continue to modernize at pace, there is an urgent need for digital transformation in the industry. If sponsors are to realize their goals of running flexible, decentralized trials (DCT), risk-based management (RBM), or adaptive trials while adopting big data, artificial intelligence / machine learning (AI/ML), the emphasis must now be on technology solutions that optimize clinical trial data workflows by bringing the technology to the data.
Increased demand for use of encapsia in decentralized trials adds more capabilities to this revolutionary platform
Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity. We’ve added new capabilities for encapsia, after we’ve seen increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI. Encapsia was designed to address the pain around remote collection, integration, and availability of disparate data.
Decentralized trials are defined by the FDA as the decentralization of clinical trial operations where technology is used to communicate with study participants and collect data. These trials can be fully DCT (the study participant can participate in the entire clinical trial from their home or other convenient location) or hybrid DCT (combine the use of both sites and remote locations and is currently the most common type of DCT being implemented).
We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group. ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence. AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing.
At encapsia, we are pleased to be working with a like-minded partner in endpoint. With both organizations focused on simplifying the user experience and management of complex trials through technology, it was a natural step to integrate our two state-of-the-art technology systems to drive innovation and generate significant efficiencies in the clinical trial space. With encapsia, site users no longer need to use a separate IRT system – they do all their work in encapsia.